The largest analysis of the impact of GLP‐1RAs and cancer risk is a retrospective cohort study of over 1.6 million T2D patients without prior diagnoses of obesity‐associated cancers (OACs) treated with GLP‐1 RAs in addition to other hypoglycemic agents from March 2005 to November 2018. Here, GCG is linked to type 2 diabetes mellitus.